The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Abstract mRNA vaccines represent a promising alternative to conventional vaccine
approaches because of their high potency, capacity for rapid development and potential for …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Immunotherapy strategies that use cell‐based delivery systems have sparked much interest
in the treatment of malignancies, owing to their high biocompatibility, excellent tumor …

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …

In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and
highly efficient class of drugs. Several recently published studies emphasize the potential …